Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1536P - Biological processes associated with the efficacy of sunitinib plus nivolumab in soft-tissue sarcoma: Correlative studies of the IMMUNOSARC trial of Spanish (GEIS) and Italian (ISG) sarcoma groups

Date

16 Sep 2021

Session

ePoster Display

Topics

Translational Research

Tumour Site

Soft Tissue Sarcomas

Presenters

Serena Lacerenza

Citation

Annals of Oncology (2021) 32 (suppl_5): S1111-S1128. 10.1016/annonc/annonc712

Authors

S. Lacerenza1, D. Moura1, M. Peña-Chilet2, N. Hindi3, J. Dopazo2, P. Sanchez-Bustos4, G. Grignani5, J. Martinez-Trufero6, A. Redondo7, C. Valverde8, S. Stacchiotti9, A. Lopez Pousa10, L. D’Ambrosio11, H. Perez-Vega12, P. Collini13, J.A. Lopez-Martin14, J. Martin Broto15

Author affiliations

  • 1 -, Institute of Biomedicine of Seville (IBiS; CSIC, HUVR, US), 41013 - Seville/ES
  • 2 Clinical Bioinformatics Area, Hospital Virgen del Rocio, 41013 - Seville/ES
  • 3 Oncology, Fundación Jimenez Diaz University Hospital, 28040 - Madrid/ES
  • 4 Oncohematology And Genetics Department, Institute of Biomedicine of Seville (IBiS; CSIC, HUVR, US), 41013 - Seville/ES
  • 5 Division Of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Torino/IT
  • 6 Medical Oncology, HU Miguel Servet, Zaragoza/ES
  • 7 -, La Paz University Hospital, Madrid/ES
  • 8 Medical Oncology, Vall d'Hebron University Hospital, Barcelona/ES
  • 9 Adult Mesenchymal Tumor Medical Oncology Unit, Cancer Medicine Dpt, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, 20133 - Milan/IT
  • 10 -, Hospital de la Santa Creu i Sant Pau, 08041 - Barcelona/ES
  • 11 Division Of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, 10060 - Torino/IT
  • 12 -, Hospital Virgen del Rocio, 41013 - Seville/ES
  • 13 Dipartimento Di Patologia Diagnostica E Laboratorio, IRCCS Istituto Nazionale Tumori, Milano, 20133 - Milan/IT
  • 14 Medical Oncology, Hospital 12 de Octubre/, Madrid/ES
  • 15 Medical Oncology, Fundación Jimenez Diaz University Hospital, 28040 - Madrid/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1536P

Background

Immunomodulation has emerged as an active therapeutic option in some solid tumors; however, the efficacy of immunotherapy-based regimens is limited in sarcomas or restricted to a few specific subtypes. IMMUNOSARC was a phase Ib/II trial testing the double inhibition of angiogenesis (sunitinib) and PD-1/PD-L1 axis (nivolumab) in bone and soft-tissue sarcoma (STS). In this latter cohort, the trial met its primary endpoint, with 48% of patients free of progression at 6 months (m). We present here, part of the correlative studies associated with the STS cohort.

Methods

Paraffin tumor blocks were prospectively collected at baseline (before sunitinib initiation). Direct transcriptomics was performed using HTG Molecular Oncology Biomarker panel (HTG Molecular Diagnostics, Inc.; Tucson, AZ, USA). Differential gene expression was analyzed accordingly to 6-m progression-free survival (PFS).

Results

Among the 65 STS patients enrolled in the trial, 61 samples at baseline were used for this analysis. Of 2,549 transcripts analyzed, 369 genes were significantly and differently overexpressed according to 6-m PFS: 192 and 177 genes were associated with better or worse outcome, respectively. Gene ontology (GO) analysis showed that genes associated with worse PFS were related with biological processes, such as DNA metabolism (GO:0006259; combined score (CS): 771.10, p<0.001), DNA repair (GO:0006281; CS: 292.93, p<0.001), cellular response to DNA damage (GO:0006974; CS: 231.39, p<0.001), or positive regulation of cell cycle (GO:0090068; CS: 512.62, p<0.001). On the other hand, genes associated with a PFS >6-m were related with GO biological processes such as cellular response to cytokine stimulus (GO:0071345; CS: 160.05, p<0.001) or cytokine-mediated signaling (GO:0019221; CS: 134.90, p<001).

Conclusions

DNA damage repair (DDR) and cell cycle-related processes seemed to be associated with worse outcome to immunotherapy-based schemes. Further studies are warranted to understand the potential added value of cell cycle inhibitors or DDR-targeted therapies to immunotherapy.

Clinical trial identification

NCT03277924.

Editorial acknowledgement

Legal entity responsible for the study

J. Martín-Broto.

Funding

Sarcoma Foundation of America - SFA.

Disclosure

D. Moura: Financial Interests, Personal, Other: Pfizer. N. Hindi: Financial Interests, Institutional, Research Grant: PharmaMar; Financial Interests, Personal, Invited Speaker: PharmaMar; Financial Interests, Institutional, Research Grant: Eisai; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Sponsor/Funding: Eli Lilly; Financial Interests, Institutional, Sponsor/Funding: AROG; Financial Interests, Institutional, Sponsor/Funding: Bayer; Financial Interests, Institutional, Sponsor/Funding: Eisai; Financial Interests, Institutional, Sponsor/Funding: Lixte ; Financial Interests, Institutional, Sponsor/Funding: Karyopharm; Financial Interests, Institutional, Sponsor/Funding: Deciphera; Financial Interests, Institutional, Sponsor/Funding: GSK; Financial Interests, Institutional, Sponsor/Funding: Novartis; Financial Interests, Institutional, Sponsor/Funding: Blueprint; Financial Interests, Institutional, Sponsor/Funding: Nektar; Financial Interests, Institutional, Sponsor/Funding: Forma; Financial Interests, Institutional, Sponsor/Funding: Amgen; Financial Interests, Institutional, Sponsor/Funding: Daiichi Sankyo; Financial Interests, Personal, Advisory Board: PharmaMar; Financial Interests, Personal, Other: PharmaMar. G. Grignani: Financial Interests, Institutional, Research Grant: PharmaMar; Financial Interests, Personal, Other: PharmaMar; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Personal, Other: Lilly; Financial Interests, Personal, Other: Pfizer; Financial Interests, Personal, Other: Bayer; Financial Interests, Personal, Other: Eisai. A. Redondo: Financial Interests, Institutional, Research Grant: PharmaMar; Financial Interests, Personal, Other: PharmaMar; Financial Interests, Personal, Other: Lilly; Financial Interests, Personal, Other: Novartis; Financial Interests, Personal, Other: Amgen; Financial Interests, Personal, Other: AstraZeneca; Financial Interests, Personal, Other: Tesaro; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Personal, Other: Roche; Financial Interests, Institutional, Research Grant: Eisai. S. Stacchiotti: Financial Interests, Personal and Institutional, Other: Bayer; Financial Interests, Personal and Institutional, Other: Lilly; Financial Interests, Personal and Institutional, Other: PharmaMar; Financial Interests, Institutional, Research Grant: GlaxoSmithKline; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Research Grant: Pfizer. J.A. Lopez-Martin: Financial Interests, Personal, Other: PharmaMar; Financial Interests, Personal, Other: Eli Lilly; Financial Interests, Personal, Other: Bayer; Financial Interests, Personal, Other: Eisai; Financial Interests, Personal, Other: Novartis; Financial Interests, Personal, Other: BMS; Financial Interests, Personal, Other: MSD; Financial Interests, Personal, Other: Roche; Financial Interests, Personal, Other: Celgene; Financial Interests, Personal, Other: Pierre Fabre; Financial Interests, Personal, Other: Pfizer; Financial Interests, Personal, Other: GSK; Financial Interests, Personal, Other: Daiichi Sankyo; Financial Interests, Personal, Other: Amgen; Financial Interests, Personal, Other: Chobani. J. Martin Broto: Financial Interests, Personal, Expert Testimony, Honoraria: Lilly; Financial Interests, Personal, Expert Testimony, Honoraria: PharmaMar; Financial Interests, Personal, Expert Testimony, Honoraria: Eisai; Financial Interests, Personal, Expert Testimony, Honoraria: Bayer; Financial Interests, Personal, Invited Speaker: PharmaMar; Financial Interests, Institutional, Invited Speaker: PharmaMar; Financial Interests, Institutional, Invited Speaker: Eisai; Financial Interests, Institutional, Invited Speaker: Novartis; Financial Interests, Institutional, Invited Speaker: IMMIX Biopharma; Financial Interests, Institutional, Invited Speaker: Lixte; Financial Interests, Institutional, Invited Speaker: Karyopharm; Financial Interests, Institutional, Invited Speaker: Bayer; Financial Interests, Institutional, Invited Speaker: Celgene; Financial Interests, Institutional, Invited Speaker: Pfizer; Financial Interests, Institutional, Invited Speaker: BMS; Financial Interests, Institutional, Invited Speaker: Blueprint; Financial Interests, Institutional, Invited Speaker: Deciphera; Financial Interests, Institutional, Invited Speaker: Nektar; Financial Interests, Institutional, Invited Speaker: Forma; Financial Interests, Institutional, Invited Speaker: Amgen; Financial Interests, Institutional, Invited Speaker: Daiichi Sankyo; Financial Interests, Institutional, Invited Speaker: Lilly; Financial Interests, Institutional, Invited Speaker: Arog; Financial Interests, Institutional, Invited Speaker: Adaptimmune; Financial Interests, Institutional, Invited Speaker: GSK. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.